What Cytiva does

Cytiva is a global provider of technologies and services for biomanufacturing, supplying biopharmaceutical developers with the equipment, consumables, reagents, and automation needed to take therapies from discovery through commercial production. Founded in 2019 when Danaher acquired GE Healthcare's Biopharma business, Cytiva traces a 60-year heritage in bioprocess technology and today operates approximately 15,000 associates across 41 countries, with 36 manufacturing sites and 23 R&D centers. Its core platforms include ÄKTA chromatography systems, Biacore 8S/8S+ surface plasmon resonance systems, ReadyToProcess WAVE bioreactors with single-use Cellbag containers, the FlexFactory end-to-end platform, ELEVECTA cell lines for adeno-associated virus (AAV) production, the SA25 aseptic filling workcell, and Figurate SCADA software co-developed with Rockwell Automation. The 2023 integration of Pall Life Sciences added a complementary portfolio in filtration, separation, and fluid handling, and regulatory milestones include FDA Advanced Manufacturing Technology (AMT) designation for ELEVECTA; Cytiva states that six of seven approved CAR-T cell therapies use its technology.

Cytiva monetizes across three primary streams: capital equipment (single-use bioreactors, chromatography skids, fill-finish workcells, SPR instruments), recurring consumables and reagents (resins, filtration media, single-use assemblies) that drive an annuity-like base, and services spanning installation, qualification, maintenance, training, and regulatory/compliance documentation. Commercial motion combines direct enterprise field sales for large biopharma and CDMOs with direct-to-customer eCommerce for researchers and smaller developers, plus integrations with procurement platforms such as Coupa and Jaggaer. Danaher's parent-level projection of $500-800M in annual software revenue by 2029 frames a longer-term monetization lever on the installed base, supported by the Figurate SCADA, Cytiva Data Bridge, Biacore Insight, and digital twin tooling set.

The customer base spans large biopharma (e.g., Kite/Gilead using the Sefia platform), contract development and manufacturing organizations (Chime Biologics), gene therapy developers (SR-TIGET, Yoshindo), and a long tail of emerging biotech and academic researchers. Cytiva's strategic posture is reinforced through the Danaher Beacon program (with SR-TIGET in the EU), ARPA-H CAR-T funding collaboration, and an active partnership and M&A program with names including Multiply Labs, Cellular Origins, Asimov, Nuclera, Domainex, Aldevron, IDT, Veeda Lifesciences, Fida Bioscience, and recent acquisitions of Intermountain Life Sciences, GoSilico, Vanrx Pharmasystems, and CEVEC Pharmaceuticals.

Name

Cytiva

Legal name

Global Life Sciences Solutions USA LLC

Website

https://cytivalifesciences.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Cytiva is a global bioprocess technology and services provider, supplying biopharmaceutical developers with equipment, consumables, automation, and fill-finish solutions used to manufacture biologics, vaccines, and cell and gene therapies. The company operates approximately 15,000 associates across 41 countries as a wholly-owned subsidiary of Danaher.

Ownership category

akta.pro rank

Product category

Bioprocessing Equipment and Consumables

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES) (HLAAAJAE)

akta.pro secondary industries

Process Analytical Technology (PAT) & In-Line/At-Line Analytics (spectroscopy, sensors, monitoring) (HLAAAJAD), Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces) (HLAAAJAG), Viral Clearance, Sterile Filtration & Bioburden Control Technologies (HLAAAJAL)

Keywords

• Bioprocessing equipment
• Biopharmaceutical manufacturing
• Chromatography systems
• Cell culture bioreactors
• Filtration consumables

Headquarters

HQ city

Marlborough

HQ country

United States

HQ region

North America

Offices10 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Bioprocessing Equipment and Instruments: Cytiva generates revenue from selling bioprocessing equipment including bioreactors (ReadyToProcess WAVE, X-platform), chromatography systems (ÄKTA pure, ÄKTA flux), filtration systems, and protein analysis instruments (Biacore SPR systems). Equipment sales are typically capital expenditures for biopharma manufacturers and CDMOs, often with multi-year procurement cycles.
2. Consumables and Reagents: A significant revenue stream from single-use consumables including bioreactor bags (Cellbag), chromatography resins, filtration membranes and capsules, cell culture media and feeds, microcarriers, SPR sensor chips, electrophoresis reagents, and other disposables. Consumables represent recurring revenue driven by the utilization frequency of installed equipment.
3. Services, Maintenance, and Support: Cytiva provides equipment service, qualification, remote support, regulatory consulting, and process development services. The company operates Fast Trak centers offering process development and validation services, and provides regulatory services consulting including strategic consulting, document publishing, and lifecycle support. Service revenue includes equipment repairs, instrument qualification (IQ/OQ), and maintenance training.
4. Regulatory and Compliance Documentation Services: Subscription-based access to regulatory support documentation including change control notifications (CCNs), regulatory support files (RSFs), validation guides, extractables information, and compliance documentation for single-use systems. These subscriptions support customers in regulated biopharma manufacturing environments.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

Cytiva manufactures and supplies bioprocessing technologies and services for biopharmaceutical manufacturing, spanning upstream bioprocessing (single-use bioreactors, cell culture media, microcarriers), downstream processing (chromatography systems, filtration, tangential flow filtration), protein analysis (SPR systems), and aseptic filling. The company also provides cell lines for viral vector and gene therapy manufacturing, automation/SCADA software, and Fast Trak process development services for researchers, biotech firms, and biopharma manufacturers.

Product overview

Cytiva provides a unified portfolio of biopharmaceutical manufacturing technologies under Danaher, organized around integrated platform solutions spanning discovery through delivery. The core offerings include Biacore 8 series SPR systems (8S and 8S+) for protein interaction analysis paired with Biacore Insight Software; ÄKTA pure chromatography systems and ÄKTA readyflux TFF systems for downstream purification; ReadyToProcess WAVE and iCELLis Nano bioreactors with Cellbag containers and Cytodex microcarriers for upstream cell culture; Figurate SCADA (with Rockwell Automation) for process automation; and aseptic filling solutions including SA25 Workcell and Microcell Vial Filler. ELEVECTA producer and transient cell lines enable AAV-based gene therapy manufacturing, while FlexFactory provides end-to-end manufacturing platforms. The 2023 integration of Pall Life Sciences expanded Cytiva's filtration, chromatography, and single-use consumables portfolio. Cytiva also offers supporting software including UNICORN, Data Bridge, and Biacore Simul8, with Fast Trak services for process development and validation.

Differentiator

Problem solved

Functional benefit

Products and services

• Biacore 8S SPR System Surface plasmon resonance instrument for label-free molecular interaction analysis, capable of screening 384 proteins in approximately 15 minutes with integrated plate handling and automated workflows, targeted at drug discovery researchers and biopharma scientists.
• Biacore 8S+ SPR System Enhanced surface plasmon resonance system combining rapid screening and high-quality molecular characterization in a single instrument, designed for drug discovery applications.
• ELEVECTA Producer Cell Line Stable cell line for inducible AAV production with all required genes stably integrated into the host cell genome, requiring only an induction step to initiate AAV production, used for gene therapy manufacturing.
• ELEVECTA Transient Cell Line Flexible cell line for producing viral vectors using triple transfection, designed to minimize development time and advance candidates to clinical trials; received FDA Advanced Manufacturing Technology designation and reduces encapsidated host cell DNA by up to 99% compared to commercially available cell lines.
• Figurate SCADA System Supervisory control and data acquisition platform jointly developed with Rockwell Automation to eliminate digital bottlenecks in biopharmaceutical manufacturing through open architecture, native FactoryTalk interoperability, scalable growth from process development to commercial manufacturing, and cGMP compliance support.
• ReadyToProcess WAVE Bioreactor Single-use bioreactor system using Cellbag containers for non-invasive animal cell cultivation with rocking motion technology, used for cell culture and bioprocessing applications.
• iCELLis Nano Bioreactor Adherent cell single-use bioreactor for high-density cell culture applications including viral vector and cell therapy manufacturing.
• ÄKTA pure Chromatography Systems Automated liquid chromatography systems for protein purification designed for research and production purposes from early development through commercial release.
• ÄKTA readyflux TFF Systems Fully automated tangential flow filtration solutions combining single-use flow kits and intuitive software for streamlined bioprocessing workflows, reducing batch turnaround time and contamination risk.
• Allegro Connect Systems Single-use automated filtration systems including depth filtration and virus filtration systems for robust process control during clarification and downstream processing.
• SA25 Aseptic Filling Workcell Standardized gloveless filler with specialized robots that fill and close nests of vials, syringes, or cartridges for flexible contamination control and accelerated time to market.
• Microcell Vial Filler Closed robotic isolator for small-batch pharmaceutical vial filling designed for personalized medicines and clinical trial material manufacturing.
• Drug Product Filtration System System for terminal sterilization prior to filling with maximum product recovery, supporting EU GMP Annex 1 requirements with automated PUPSIT.
• FlexFactory Platform End-to-end biomanufacturing platform combining upstream and downstream technologies for accelerated therapeutics development and scalable production, used by emerging and large biopharma for biosimilar and biologic manufacturing.
• Cellbag Bioreactor Containers Presterilized single-use bioreactor bags available in Bioclear 10, Bioclear 11, and Fortem film formulations for use with ReadyToProcess WAVE systems.
• Cytodex Microcarriers Microcarrier beads for anchorage-dependent cell culture, including Cytodex 1 for general use and Cytodex 3 for difficult-to-culture cells, used in bioreactor cell culture applications.
• X-Platform Bioreactors Single-use upstream bioprocessing solutions for manufacturing cell therapies, viral vectors, and monoclonal antibodies, offering scalable capacity for process development and commercial manufacturing.
• CAP Ad Cell Line Proprietary cell line based on human suspension cells tailored for adenoviral vector production that minimizes replication-competent adenovirus, used in gene therapy and vaccine manufacturing.
• Fast Trak Process Development and Validation Services Process development, scale-up, and validation services delivered through Cytiva's global Fast Trak centers, including the expanded Bengaluru facility, supporting biopharma customers with upstream and downstream workflows.
• Regulatory and Compliance Documentation Services Subscription-based access to regulatory support documentation including change control notifications (CCNs), regulatory support files (RSFs), validation guides, and extractables information for single-use systems in regulated biopharma manufacturing environments.

Quantifiable outcome

• The ELEVECTA transient cell line reduces encapsidated host cell DNA by up to 99% compared to commercially available cell lines, supporting a stronger product quality profile in AAV manufacturing.
• +4 more outcomes

Named customers8 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability7 records

Feature11 records

Partnerships

16 partnerships are on record, tiered core, flagship and minor.

• Rockwell AutomationcoreTechnology or Integration · 29 April 2026Cytiva and Rockwell Automation jointly launched the Figurate SCADA system, a supervisory control and data acquisition platform designed to remove digital bottlenecks in biopharmaceutical manufacturing. The platform features open architecture for third-party instrument integration, native interoperability with Cytiva bioprocessing equipment and Rockwell's FactoryTalk software suite, scalable growth from process development to commercial manufacturing, cGMP compliance support, and centralized alarms with real-time monitoring. The Figurate SCADA is available globally.
• San Raffaele Telethon Institute for Gene Therapy (SR-TIGET)flagshipStrategic or Co-development Partner · 23 March 2026Cytiva, a Danaher company, and SR-TIGET launched a collaboration to advance next-generation genomic medicine platforms, establishing the first Danaher Beacon on the European continent. The initiative focuses on optimizing lentiviral vector production and homology-directed repair-based gene editing in hematopoietic stem cells, combining SR-TIGET's scientific leadership with Cytiva's manufacturing expertise alongside partners Aldevron and IDT. The multi-year collaboration aims to address bottlenecks in cell and gene therapy translation, scalability, and reproducibility. This is the first Danaher Beacon in the EU.
• AsimovcoreStrategic or Co-development PartnerCytiva announced a partnership with synthetic biology company Asimov for optimized biologics production, combining Asimov's genetic design tools and proprietary circuitry with Cytiva's bioprocessing platform capabilities to advance manufacturing of complex biologics.
• NucleracoreStrategic or Co-development PartnerCytiva and Nuclera entered a collaboration to accelerate protein production, purification, and characterization for drug research and development. The companies demonstrated the ability to produce and analyze key proteins within five days — significantly faster than traditional methods — by integrating Nuclera's eProtein Discovery benchtop system with Cytiva's technologies. Nuclera also installed its system at Domainex as its first CRO implementation.
• YoshindocoreStrategic or Co-development PartnerCytiva and Yoshindo established a biosimilar manufacturing system in Japan using Cytiva's FlexFactory technology. The system aims to start production by 2028, focusing on biosimilar active pharmaceutical ingredients for antibody drugs. This collaboration supports Japan's domestic biosimilar manufacturing capacity and aligns with growth forecasts for the biosimilar market.
• Chime BiologicscoreStrategic or Co-development PartnerChime Biologics deepened its collaboration with Cytiva to boost manufacturing capacity, leveraging Cytiva's solutions to expand bioprocessing capabilities for biopharmaceutical manufacturing.
• DomainexminorChannel Partner/ Reseller/ DistributorDomainex installed Cytiva's eProtein Discovery system as its first CRO implementation for protein characterization, demonstrating the integration of Cytiva technology within a contract research organization.
• Swedish Government (Testa Center)coreStrategic or Co-development PartnerThe Testa Center in Uppsala, Sweden is a public-private initiative between the Swedish government and Cytiva. It launched the Testa Challenge program to address scalability challenges in adeno-associated virus (AAV) manufacturing for gene therapy applications. Aldevron supplies production-grade plasmid DNA to participants in the three-week fully funded program.
• Multiply LabscoreStrategic or Co-development PartnerCytiva partnered with Multiply Labs to develop robotic cluster production systems for next-generation biological therapies. Multiply Labs deploys robotic automation for cell therapy manufacturing, with Cytiva contributing bioprocessing expertise as part of the collaboration that also includes companies like AstraZeneca, NVIDIA, Thermo Fisher Scientific, Kyverna Therapeutics, Legend Biotech, and WuXi STA.
• ARPA-H (Advanced Research Projects Agency for Health)flagshipStrategic or Co-development PartnerCytiva received an award from ARPA-H with the ambition to help transform CAR-T cell therapy for solid tumors. This US government funding supports development of in vivo cell therapy programs using advanced gene editing and delivery technologies. Cytiva is among notable recipients including immunoVec, Tessera Therapeutics, and Nkarta receiving funding up to $48 million.
• Cellular OriginscoreStrategic or Co-development PartnerCytiva is collaborating with Cellular Origins on the Constellation robotic automation platform for scalable, end-to-end cell and gene therapy manufacturing. Cytiva is part of an Innovate UK-funded consortium including Fresenius Kabi, Thermo Fisher Scientific, and Wilson Wolf/ScaleReady to advance fully-automated, robotically-operated CGT manufacturing. Cellular Origins secured $40 million Series A funding with JJDC and Highland Europe.
• Kite, a Gilead companycoreStrategic or Co-development PartnerCytiva developed its Sefia cell therapy manufacturing platform in collaboration with Kite, a Gilead company, to support CAR-T cell therapy manufacturing. Kite is a leading cell therapy developer with approved CAR-T products.
• AldevroncoreStrategic or Co-development PartnerAldevron is a partner in the SR-TIGET collaboration, supplying production-grade plasmid DNA to participants in the Testa Challenge program and contributing to the broader genomic medicine platform development alongside Cytiva and SR-TIGET.
• Integrated DNA Technologies (IDT)coreStrategic or Co-development PartnerIDT is a partner in the SR-TIGET genomic medicine collaboration, contributing gene editing and nucleic acid synthesis expertise alongside Cytiva and SR-TIGET for lentiviral vector production and homology-directed repair-based gene editing.
• Uppsala UniversitycoreStrategic or Co-development PartnerCytiva and Uppsala University held their 2026 management dialogue to review outcomes of their strategic partnership formally established in November 2024. The collaboration builds on several decades of collaboration in life sciences, chemistry, biology, and biotechnology, with both parties exploring new areas including automation. The partnership addresses joint funding opportunities, external partnerships, and forms for evaluation and follow-up to strengthen academia-industry knowledge exchange.
• Veeda LifesciencesminorStrategic or Co-development PartnerCytiva and Veeda Lifesciences established a new host cell protein (HCP) services center, combining Cytiva's analytical capabilities with Veeda's contract research expertise to support biopharma companies in HCP characterization and compliance.

Scale indicators12 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Sartorius AG: Sartorius is a global bioprocessing equipment and consumables leader, with a bioprocess solutions division that directly competes with Cytiva in bioreactors, single-use systems, filtration, and cell line/media products for biopharma manufacturing.
• Thermo Fisher Scientific: Thermo Fisher's Life Sciences / Bioproduction businesses compete head-to-head with Cytiva in single-use technologies, bioreactors, chromatography, and downstream processing consumables for biopharma manufacturing customers.
• Repligen Corporation: Repligen is a focused bioprocessing pure-play competing with Cytiva in chromatography resins and columns, filtration systems, and process analytics for biopharmaceutical manufacturing.
• Merck KGaA (MilliporeSigma Life Science): Merck's Life Science segment (MilliporeSigma) is a direct competitor in upstream cell culture media, single-use bioreactors, filtration, chromatography, and process development services for biopharma.

Broad incumbents

• Agilent Technologies: Agilent competes with Cytiva's Biacore protein analysis business in SPR, chromatography, and biopharma analytical instruments, with a broader analytical instrument and diagnostics portfolio.
• Danaher Corporation (parent): Cytiva's parent conglomerate; Danaher's broader Life Sciences and Diagnostics businesses (Beckman, Leica, Cepheid, IDT, Aldevron, Pall) overlap and integrate with Cytiva's bioprocess focus as a diversified life sciences platform.
• Waters Corporation: Waters is a leading analytical instruments and chromatography informatics company that overlaps with Cytiva's protein analysis and chromatography workflow offerings for biopharma customers.
• Bio-Techne: Bio-Techne provides proteins, reagents, and analytical tools to the biopharma research and bioprocess markets, overlapping with Cytiva's consumables and protein analysis offerings for research and process development customers.

Emerging players

• 908 Devices: 908 Devices is a smaller, focused player in bioprocess analytical and protein characterization technologies (mass spectrometry, Raman) that compete with parts of Cytiva's Biacore and PAT portfolio.

Others

• Lonza Group: Lonza is a leading CDMO and bioprocess solutions provider; while primarily a customer/competitor in CDMO services, Lonza's bioprocess and cell & gene therapy offerings create adjacent competition and partnership dynamics with Cytiva's products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cytiva

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cytiva